Triolab supplies equipment for the healthcare sector and is a leader in human diagnostics, with more than 30 years of experience on the Finnish market. The company operates in the customer segments that are important to Calmark, and sells, among other things, blood gas analyzers for maternity wards and intensive care units.

"We are very pleased with the collaboration with Triolab and it feels great that we can now reach more markets together." says Marianne Alksnis, International Sales Director at Calmark.

"We are always endeavouring to offer our customers high-quality products that provide better value for patients. Analytic quality, usability and quick results are key factors in POC diagnostics. Calmark Neo will give our customers access to a unique test platform for newborn patients," says Kai Rantanen, CEO of Triolab Oy. "We are eager to cooperate with a partner that shares our ambition to improve the care for newborn infants."

"It is very satisfying that we have been able to extend the agreement with Triolab," says Anna Söderlund, CEO Calmark. "Triolab addresses the specific customer segments that we prioritize, and has a solid experience of launching medical devices in local markets."

This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 16:00 CEST on 26 May 2020.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 213 25 35
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a reader and single-use products. The first three tests are being launched in 2020. WHO expects 1.5 billion children to be born worldwide prior to 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer decision-making support, which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.